Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Antibiotic · 1 trial · 3 indications
| Name | Type | Description |
|---|---|---|
| Antibiotic | DRUG | - |
Other specific inclusion/exclusion criteria may apply. In order to determine eligibility, further examination by the investigator is necessary. Inclusion Criteria: * Patients must have the signs and symptoms of pneumonia, with a chest xray showing a pneumonia. * The patient must have S. pneumoniae...
Antibiotic is an investigational small molecule being developed for pneumococcal pneumonia, specifically community-acquired pneumonia caused by Streptococcus pneumoniae. It is intended for patients with this specific bacterial infection, including those with gram-positive bacterial infections. The drug is currently in Phase 3 clinical development and is not yet approved.
Antibiotic is being developed by Pfizer, Inc., a biopharmaceutical company listed on the New York Stock Exchange under the ticker symbol PFE. Pfizer is conducting clinical trials to evaluate the drug's safety and efficacy in treating pneumococcal pneumonia.
Antibiotic is in Phase 3 clinical development. It has completed one Phase 3 trial, which was an uncontrolled study with 230 participants. The drug remains investigational and has not been approved by regulatory authorities for commercial use.
Antibiotic has one completed clinical trial registered under NCT00035269, titled 'New Antibiotic to Treat Patients With Community-acquired Pneumonia Due to a Specific Bacteria (S. Pneumoniae Pneumonia)'. This Phase 3 study enrolled 230 participants across the United States, Slovakia, Spain, and Taiwan, and included patients aged 13 years and older.
Antibiotic is not FDA approved. It is an investigational drug currently in Phase 3 clinical development. The completed trial, NCT00035269, was an uncontrolled study, and the drug has not yet received regulatory approval for treating pneumococcal pneumonia.